Ligand Pharmaceuticals LGND Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $153.56M+23.4% | $124.45M+156% | $48.58M+164% | -$75.86M+42.8% | -$132.62M-3,189% | ||
| $33.22M-1.6% | $33.78M-1.2% | $34.19M-2.1% | $34.91M-0.9% | $35.24M0.0% | ||
| $49.61M+5.9% | $46.85M+16.8% | $40.1M-1.0% | $40.53M-2.6% | $41.59M+1.2% | ||
| -$18M+20.7% | -$22.68M-4,018% | $579K-97.6% | $23.85M-46.0% | $44.19M+180% | ||
| $1.94M+52.4% | $1.27M+44.7% | $880K+55.2% | $567K+5.4% | $538K+10.7% | ||
| $14.75M-32.1% | $21.74M-14.1% | $25.32M— | —— | —— | ||
| -$1.35M+73.0% | -$4.99M-4.4% | -$4.78M-53.1% | -$3.12M+51.9% | -$6.49M+32.6% | ||
| $10.75M+82.7% | $5.88M-40.1% | $9.82M-10.3% | $10.96M-16.6% | $13.14M-5.5% | ||
| —— | —— | $6.54M+3.2% | $6.34M+4.2% | $6.08M+22.7% | ||
| —— | —— | —— | -$946K+10.8% | -$1.06M+18.9% | ||
| —— | —— | -$6.54M-291% | $3.42M-30.1% | $4.89M+312% | ||
| -$529K-392% | $181K+269% | $49K-46.7% | $92K-20.7% | $116K+158% | ||
| $123.5M+150% | $49.36M+54.7% | $31.92M-42.3% | $55.36M+4.7% | $52.87M-45.5% | ||
| $466K+3.1% | $452K-60.9% | $1.16M-33.5% | $1.74M-10.1% | $1.93M+6.0% | ||
| —— | —— | —— | —— | —— | ||
| $122.47M-23.3% | $159.58M+104% | $78.4M-53.6% | $168.87M-18.4% | $206.86M-9.8% | ||
| -$476.56M-26.3% | -$377.32M+5.2% | -$397.84M-338% | -$90.9M+32.7% | -$135M+6.0% | ||
| $3.43M— | $0-100% | $3.11M-87.4% | $24.75M-5.0% | $26.06M-29.8% | ||
| $27K0.0% | $27K+3.8% | $26K-13.3% | $30K+11.1% | $27K+8.0% | ||
| $22.44M+134% | $9.6M-14.2% | $11.19M+0.8% | $11.1M+1.3% | $10.95M+113% | ||
| $15.51M-0.1% | $15.53M+3.3% | $15.03M+3,648% | $401K-12.1% | $456K+7.0% | ||
| $418.84M-2.2% | $428.22M-2.7% | $440.28M+414% | $85.72M+6.9% | $80.21M-17.4% | ||
| —— | —— | —— | $2.18M+2,028% | -$113K+90.4% | ||
| $67.11M-34.6% | $102.62M+35.5% | $75.76M+53.0% | $49.53M+2,454% | -$2.1M-104% | ||
| —— | —— | —— | —— | —— | ||
| $321K0.0% | $321K+7.0% | $300K-14.8% | $352K+16.9% | $301K+14.4% | ||
| $8.3M+6.3% | $7.8M+10.9% | $7.04M-60.9% | $17.99M-7.7% | $19.49M+1.5% | ||
| $5.62M+13.4% | $4.96M+39.7% | $3.55M+51.1% | $2.35M+16.7% | $2.01M+51.2% | ||
| $1.94M+52.4% | $1.27M+44.7% | $880K+55.2% | $567K+5.4% | $538K+10.7% | ||
| -$597K+37.0% | -$948K+40.8% | -$1.6M— | —— | —— | ||
| $1.85M-4.7% | $1.94M-4.5% | $2.03M-4.4% | $2.13M-4.1% | $2.22M+4.4% | ||
| —— | $53.07M+33.3% | $39.8M+50.0% | $26.54M+100% | $13.27M— | ||
| —— | —— | —— | —— | —— | ||
| -$18M+20.7% | -$22.68M-4,018% | $579K-97.6% | $23.85M-46.0% | $44.19M+180% | ||
| —— | —— | -$6.54M-291% | $3.42M-30.1% | $4.89M+312% | ||
| —— | —— | —— | —— | —— | ||
| $3.36M-61.0% | $8.62M+325% | $2.03M-68.1% | $6.36M+7.2% | $5.93M+8.4% | ||
| $359K-64.9% | $1.02M+119% | -$5.49M+75.0% | -$21.95M-7.7% | -$20.38M-1.8% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $6.17M-55.2% | $13.79M+58.9% | $8.68M+13.9% | $7.62M0.0% | $7.62M— | ||
| $9.04M-16.8% | $10.86M+6.4% | $10.21M-34.0% | $15.47M-10.1% | $17.2M-3.5% | ||
| —— | $3.85M+9.6% | $3.51M+10.6% | $3.17M+11.9% | $2.84M+13.5% | ||
| $889.52M+22.4% | $726.71M+19.6% | $607.61M+146% | $247.03M+18.7% | $208.12M-8.1% | ||
| —— | —— | —— | —— | $5.34M-25.0% | ||
| $14.09M+37.3% | $10.26M-9.2% | $11.3M+34.5% | $8.4M-2.7% | $8.64M+16.2% | ||
| $304.69M+40.0% | $217.7M+53.4% | $141.89M+53.0% | $92.74M+82.0% | $50.95M+53.8% | ||
| $122.47M-23.3% | $159.58M+104% | $78.4M-53.6% | $168.87M-18.4% | $206.86M-9.8% | ||
| $27K0.0% | $27K+3.8% | $26K-13.3% | $30K+11.1% | $27K+8.0% | ||
| $15.51M-0.1% | $15.53M+3.3% | $15.03M+3,648% | $401K-12.1% | $456K+7.0% | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$946K+10.8% | -$1.06M+18.9% | ||
| —— | —— | —— | $2.35M-9.6% | $2.6M+46.8% | ||
| -$529K-392% | $181K+269% | $49K-46.7% | $92K-20.7% | $116K+158% | ||
| $123.03M+152% | $48.91M+59.0% | $30.76M-42.6% | $53.62M+5.3% | $50.94M-46.5% | ||
| $123.03M+152% | $48.91M+59.0% | $30.76M-42.6% | $53.62M+5.3% | $50.94M-46.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Ligand Pharmaceuticals generate?
- Ligand Pharmaceuticals (LGND) generated $123.5M in operating cash flow over the trailing twelve months.
- What is Ligand Pharmaceuticals's free cash flow?
- After $466.0K of capital expenditures, Ligand Pharmaceuticals's free cash flow was $123.0M over the trailing twelve months, up 141.5% year over year.
- Where does Ligand Pharmaceuticals's cash flow data come from?
- Every line is extracted from Ligand Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
